R P Riechelmann1, A Del Giglio. 1. Internal Medicine, Federal University of Sao Paulo, Sao Paulo, Brazil. rachelri@terra.com.br
Abstract
BACKGROUND: Drug-drug interactions (DDIs) comprise an important problem in medical oncology practice. We systematically reviewed the frequency of DDIs in oncology. METHODS: We searched PubMed for eligible articles and on-line databases for abstracts of major oncology meetings. RESULTS: Eight studies reported on the frequency of DDIs: six evaluated the frequency of potential DDIs, while two studies reported on real DDIs, i.e. interactions that had clinical consequences. Studies of potential DDIs found that approximately one-third of patients are exposed to dangerous drug doublets, with the most common ones involving warfarin and anticonvulsants. One study of real DDIs found that 2% of hospitalized cancer patients had a DDI as the cause of admission. CONCLUSIONS: Drug interactions comprise an important issue in oncology, with approximately one-third of ambulatory cancer patients being at risk of DDIs. Data are limited on the clinical consequences of drug interactions among cancer patients.
BACKGROUND: Drug-drug interactions (DDIs) comprise an important problem in medical oncology practice. We systematically reviewed the frequency of DDIs in oncology. METHODS: We searched PubMed for eligible articles and on-line databases for abstracts of major oncology meetings. RESULTS: Eight studies reported on the frequency of DDIs: six evaluated the frequency of potential DDIs, while two studies reported on real DDIs, i.e. interactions that had clinical consequences. Studies of potential DDIs found that approximately one-third of patients are exposed to dangerous drug doublets, with the most common ones involving warfarin and anticonvulsants. One study of real DDIs found that 2% of hospitalized cancerpatients had a DDI as the cause of admission. CONCLUSIONS: Drug interactions comprise an important issue in oncology, with approximately one-third of ambulatory cancerpatients being at risk of DDIs. Data are limited on the clinical consequences of drug interactions among cancerpatients.
Authors: Jane R Kenny; Sophie Mukadam; Chenghong Zhang; Suzanne Tay; Carol Collins; Aleksandra Galetin; S Cyrus Khojasteh Journal: Pharm Res Date: 2012-03-14 Impact factor: 4.200
Authors: Heidi D Finnes; Kari G Chaffee; Timothy G Call; Wei Ding; Saad S Kenderian; Deborah A Bowen; Michael Conte; Kristen B McCullough; Julianna A Merten; Gabriel T Bartoo; Matthew D Smith; Jose Leis; Asher Chanan-Khan; Susan M Schwager; Susan L Slager; Neil E Kay; Tait D Shanafelt; Sameer A Parikh Journal: Leuk Lymphoma Date: 2016-11-08
Authors: C Riese; B Weiß; U Borges; A Beylich; R Dengler; K Hermes-Moll; M Welslau; W Baumann Journal: Support Care Cancer Date: 2017-06-09 Impact factor: 3.603